Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

By M. Duvic, Rakshandra Talpur, X. Ni, Chunlei Zhang, P. Hazarika, Cecilia Kelly, J. Chiao, John F. Reilly, J. Ricker, V. Richon and 1 more. Blood, 2007

1,033 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0d2fe14ddc7dd0130abef9816a4acd83e7c674ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

Citations in the corpus

Histone deacetylase inhibitors: molecular mechanisms of action (2007, background): “Vorinostat is the first of the new HDACi to be approved by Food and Drug Administration for the clinical use in cancer patients, namely the treatment of cutaneous T-cell lymphoma (CTCL) (Duvic et al., 2007; Garber, 2007).”
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “Some of the initial clinical studies established that hydroxamic acid-based compound vorinostat is well tolerated in patients with CTCL, and observed promising anti-cancer activities in different types of cancer, such as diffuse large B-cell lymphoma, Hodgkin lymphoma, and other haematological and s”
New and emerging HDAC inhibitors for cancer treatment. (2014, background): “The most successful clinical application of HDACis has been the use of vorinostat and romidepsin against refractory cutaneous and peripheral T cell lymphoma (52–55).”
Histone Deacetylase Inhibitors: Overview and Perspectives (2007, background): “Vorinostat (SAHA) is the first of the new HDACi to be approved by the Food and Drug Administration for clinical use in cancer patients for the treatment of cutaneous T-cell lymphoma.”
The many roles of histone deacetylases in development and physiology: implications for disease and therapy (2009, background): “HDAC inhibitors from multiple chemical classes have entered clinical trials, and SAHA (marketed as Vorinostat, brand name Zolinza) has been approved for treatment of cutaneous manifestations of advanced, refractory T-cell lymphoma in a select group of patient”
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. (2007, background): “These results are encouraging and comparable with the findings of the phase IIa trial of oral vorinostat (31% at 400 mg/d).(19) In the current trial, 33% of SS patients and 23% of those with tumor disease had objective responses, signifying activity in more aggressive CTCL forms.”
Histone Deacetylase Inhibitors as Anticancer Drugs (2017, background): “Administration of SAHA in refractory CTCL patients showed in phase II trials objective response in nearly 30% [166,167].”
A decade of exploring the cancer epigenome — biological and translational implications (2011, background): “A milestone in therapy using agents that modify the epigenome is the recent FDA approval of vorinostat (Zolinza; Merck) and romidepsin (Istodax; Celgene) for their remarkable efficacy in cutaneous T cell lymphom”